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Summary
Background—The Meta-Analysis of Radiotherapy in squamous cell Carcinomas of Head and 
neck (MARCH) showed that altered fractionation radiotherapy is associated with improved overall 
and progression-free survival compared with conventional radiotherapy, with hyperfractionated 
radiotherapy showing the greatest benefit. This update aims to confirm and explain the superiority 
of hyperfractionated radiotherapy over other altered fractionation radiotherapy regimens and to 
assess the benefit of altered fractionation within the context of concomitant chemotherapy with the 
inclusion of new trials.
Methods—For this updated meta-analysis, we searched bibliography databases, trials registries, 
and meeting proceedings for published or unpublished randomised trials done between Jan 1, 
2009, and July 15, 2015, comparing primary or postoperative conventional fractionation 
radiotherapy versus altered fractionation radiotherapy (comparison 1) or conventional fractionation 
radiotherapy plus concomitant chemotherapy versus altered fractionation radiotherapy alone 
(comparison 2). Eligible trials had to start randomisation on or after Jan 1, 1970, and completed 
accrual before Dec 31, 2010; had to have been randomised in a way that precluded prior 
knowledge of treatment assignment; and had to include patients with non-metastatic squamous cell 
carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx undergoing first-line curative 
treatment. Trials including a non-conventional radiotherapy control group, investigating 
hypofractionated radiotherapy, or including mostly nasopharyngeal carcinomas were excluded. 
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Trials were grouped in three types of altered fractionation: hyperfractionated, moderately 
accelerated, and very accelerated. Individual patient data were collected and combined with a 
fixed-effects model based on the intention-to-treat principle. The primary endpoint was overall 
survival.
Findings—Comparison 1 (conventional fractionation radiotherapy vs altered fractionation 
radiotherapy) included 33 trials and 11 423 patients. Altered fractionation radiotherapy was 
associated with a significant benefit on overall survival (hazard ratio [HR] 0·94, 95% CI 0·90–
0·98; p=0·0033), with an absolute difference at 5 years of 3·1% (95% CI 1·3–4·9) and at 10 years 
of 1·2% (−0·8 to 3·2). We found a significant interaction (p=0·051) between type of fractionation 
and treatment effect, the overall survival benefit being restricted to the hyperfractionated group 
(HR 0·83, 0·74–0·92), with absolute differences at 5 years of 8·1% (3·4 to 12·8) and at 10 years of 
3·9% (−0·6 to 8·4). Comparison 2 (conventional fractionation radiotherapy plus concomitant 
chemotherapy versus altered fractionation radiotherapy alone) included five trials and 986 patients. 
Overall survival was significantly worse with altered fractionation radiotherapy compared with 
concomitant chemoradiotherapy (HR 1·22, 1·05–1·42; p=0·0098), with absolute differences at 5 
years of −5·8% (−11·9 to 0·3) and at 10 years of −5·1% (−13·0 to 2·8).
Interpretation—This update confirms, with more patients and a longer follow-up than the first 
version of MARCH, that hyperfractionated radiotherapy is, along with concomitant 
chemoradiotherapy, a standard of care for the treatment of locally advanced head and neck 
squamous cell cancers. The comparison between hyperfractionated radiotherapy and concomitant 
chemoradiotherapy remains to be specifically tested.
Introduction
Modifications of radiotherapy fractionation have long been studied in various disease sites, 
including head and neck cancer. Altered fractionation radiotherapy is believed to be effective 
through two mechanisms that together improve the therapeutic ratio: the delivery of small 
fractions twice per day reduces the frequency of late toxicity, allowing for higher total doses 
of radiation to be delivered than can be achieved with conventional dosing; and the 
shortening of the overall treatment time limits tumour repopulation. Both strategies could 
improve tumour control. Many randomised trials have assessed these radiotherapy schedules 
and provided conflicting results regarding tumour control and survival, mostly because of 
trial heterogeneity and small sample sizes. However, these trials have confirmed that 
fractionation modifications were usually associated with more frequent acute side-effects but 
similar or less frequent late toxicity than conventional fractionation radiotherapy.1–4
For squamous cell carcinoma of the head and neck, the Meta-Analysis of Radiotherapy in 
Carcinomas of Head and neck (MARCH)1 showed that altered fractionation radiotherapy is 
associated with improved overall survival and progression-free survival when compared with 
conventional fractionation radiotherapy. Trials were grouped according to the type of altered 
fractionation used: hyperfractionation, which used a higher total dose than the reference 
group, using twice daily fractions but with the same overall treatment time; moderate 
acceleration, in which the total dose was unchanged (±5%) but delivered more quickly 
(generally about 1 week faster) than in the reference group; and very accelerated 
radiotherapy with dose reduction, in which radiotherapy duration was shortened by 50% or 
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more and total dose reduced by about 15% (range 11–23) compared with the reference 
groups. The meta-analysis1 noted a significant interaction between treatment effect and 
altered fractionation regimens, the survival benefit being restricted to the hyperfractionation 
subgroup. The reasons for the superiority of hyperfractionation over other types of altered 
fractionation remained unclear, and hyperfractionation has not become a standard of care, 
mostly due to logistical issues, such as the difficulty to find two slots per day on machines or 
patient management between fractions, which favoured the delivery of con comitant 
chemoradiotherapy over hyperfractionation.
Because several new trials have been published since the original publication of MARCH, 
we provide an update, aiming to confirm and explain the superiority of hyperfractionation 
over the other altered fractionation regimens, to assess the benefit of altered fractionation 
within the context of concomitant chemotherapy or postoperative trials, and to provide a 
direct comparison of altered fractionation with conventional fractionation concomitant 
chemoradiotherapy.
Methods
Search strategy and selection criteria
This updated meta-analysis was done according to a prespecified protocol. The method is 
similar to our previous publications.1,5–7
We searched PubMed, Web of Science, the Cochrane Controlled Trials meta-register, 
ClinicalTrials.gov, and meeting proceedings for randomised trials published or presented 
between Jan 1, 2009, and July 15, 2015 (appendix p 2). To be eligible, published and 
unpublished trials had to compare primary or postoperative conventional fractionation 
radiotherapy with altered fractionation radiotherapy (with or without the same concomitant 
chemotherapy in both groups; comparison 1) or conventional fractionation radiotherapy plus 
con comitant chemoradiotherapy versus altered fractionation radio therapy without 
concomitant chemo therapy (comparison 2). Eligible trials had to have been randomised in a 
way that precluded prior knowledge of treatment assignment, started randomisation on or 
after Jan 1, 1970, completed accrual before Dec 31, 2010, and included patients with non-
metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx 
undergoing first-line curative treatment. Eligible trials were grouped in three types of altered 
fractionation: hyperfractionated, moderately accelerated, and very accelerated. We excluded 
trials including a non-conventional radiotherapy control group or including mostly 
nasopharyngeal carcinomas. We also excluded trials investigating hypofractionated 
radiotherapy, defined as doses per fraction higher than 2·5 Gy, due to its use mostly in 
palliative cases.
Data extraction and checking
Individual patient data were requested for each eligible trial by the meta-analysis team and 
for all randomly assigned patients. Data collected included patient and tumour 
characteristics, dates of randomisation, failures and death, treatment group allocated, details 
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about treatments received, and acute and late toxicities. Follow-up information was updated 
whenever possible.
All data were checked with a standard procedure,6,8 which follows the recommendations of 
the Cochrane working group on meta-analysis using individual patient data. Internal 
consistency was checked (chronology of dates, outlier values, etc) and data were compared 
with the trial protocol and published reports. Randomisation validity was assessed by 
checking patterns of treatment allocation and balance of baseline characteristics between 
treatment groups. Follow-up of patients was also compared between treatment groups.8 
Every question raised by the checking procedure was discussed with the trialists. Each trial 
was reanalysed and the analyses were sent to the trialists for validation.
Outcomes
The primary endpoint was overall survival, defined as the time from randomisation until 
death from any cause. Secondary endpoints were progression-free survival; local, regional, 
and loco-regional failures; distant failure; cancer and non-cancer mortality; and non-
haematological toxicities. Progression-free survival was defined as the time from 
randomisation to first progression (locoregional or distant) or death from any cause. Living 
patients without events were censored at their date of last follow-up. Events considered were 
local failure alone for local failures; regional failure or concomitant regional and local 
failures without distant failure for regional failures; and distant failure, either alone or 
combined with local or regional failures, for distant failures. Only the first event was 
recorded, then patients with an additional event other than the one studied were censored at 
the time of that event. Patients without failure events were censored at their time of last 
follow-up. Non-cancer mortality was defined as deaths without previous progression and 
resulting from known causes other than the treated head and neck cancer. Cancer mortality 
included deaths from any cause with previous progression and deaths from the treated head 
and neck cancer. Deaths from unknown cause without previous progression were regarded as 
cancer mortality if they occurred within 5 years after randomisation, and as non-cancer 
mortality otherwise. Only trials with at least 80% of available data were deemed eligible for 
nonhaematological toxicity analysis. If at least 2000 patients were included in those trials, 
toxicity was analysed. Moreover, for late toxicities, patients with a follow-up shorter than 6 
months were excluded. Secondary endpoints also included HPV status and smoking status, 
which were available for only five trials and are currently being analysed, and compliance, 
which was collected but has not been analysed yet. Those endpoints will be reported 
separately.
Statistical analysis
All analyses were done on an intention-to-treat basis. With 12 000 patients (and at least 7000 
deaths), an absolute improvement in survival from 30% to 33% at 5 years could be detected 
with a power of 99·9% (two-sided log-rank test, α=5%). We estimated median follow-up 
with the reverse Kaplan-Meier method.9 Analyses were stratified by trial. We calculated 
individual and overall pooled hazard ratios (HRs) with 95% CIs through a fixed-effects 
model using the log-rank expected number of events and variance.10 A similar model was 
used to estimate odds ratios (ORs) for the comparison of toxicity between groups, and 
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incidences of toxicity in the experimental group were calculated using the incidence in the 
control group and the OR.10,11 The χ2 heterogeneity test and I2 statistic were used to 
investigate the overall heterogeneity between trials.12 In case of significant heterogeneity 
(p<0·10), trials that had a 95% CI that did not overlap with the 95% CI of the global HR 
were excluded. If heterogeneity was still significant, we used a random-effects model.6 
Methods used to estimate cancer and non-cancer mortality and to draw stratified curves were 
similar to the ones used in the previous meta-analysis (appendix p 3).1,13,14 Methods used to 
study survival within and after 5 years were similar to those used to study cancer and non-
cancer mortality (appendix p 3). In addition to the fixed-effects model, a competing risk 
model was used for local, regional, and distant failure.15 To estimate 5-year and 10-year 
absolute differences in all outcomes, actuarial survival rates were computed on all patients 
and the HR at the corresponding time period was used to compute survival in each 
group.1,13,14 We also estimated restricted mean survival times, a new method to estimate 
absolute benefit.16–18 Details about those methods are reported in the appendix (p 3).
We did subset analyses to study the interaction between treatment effect and trial level 
characteristics, using a test of heterogeneity among the different groups of trials. We 
computed residual heterogeneity within trial subgroups by subtracting the χ2 statistic of the 
heterogeneity test between groups from the χ2 statistic of the overall heterogeneity test.19 
Predefined subsets were the altered fractionation regimen (hyperfractionation, moderately 
accelerated radiotherapy, or very accelerated radiotherapy), the use of concomitant 
chemotherapy, and the performance of primary surgery. We estimated interaction between 
treatment effect and patient subgroups (according to age, sex, performance status, primary 
site, and overall stage) in a Cox model stratified by trial and containing treatment effect, 
covariate effect (eg, age), and treatment–covariate interaction (one-stage model method).20 
An unplanned subgroup analysis on regional failure was performed in patient with node-
positive disease.
All p values were two-sided. Analyses were done using SAS, version 9.3.
Role of the funding source
The funding sources had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The submission of the paper for publication was 
decided by the MARCH collaborative group. PB, BL, and J-PP had access to the raw data. 
The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. All authors have seen and approved 
the final version and, after consultation with the collaborators, agreed to submit for 
publication.
Results
We identified 26 new trials published between 1995 and 2016 that were not included in the 
original MARCH analysis. We did not collect data from four trials (n=185): three21–23 
because we could not contact the investigators and one24 because the study was closed early 
with very short follow-up. Five other trials were excluded after blind review by the steering 
committee because of the absence of survival or randomisation dates,25,26 issues with the 
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randomisation process,27,28 or very short and different follow-up between groups,29 leaving 
17 new trials: 15 published30–44 and two unpublished (CHARTWEL, EORTC 2296245). We 
also included two postoperative trials46,47 that had previously been identified1 but not 
included and excluded a third trial48 because of unavailable data (appendix p 16). As such, 
19 new trials were included (table 1). Updated data could be obtained for nine trials2–4,49–54 
of the 15 included in the first MARCH meta-analysis, increasing median follow-up from 6·1 
years (IQR 4·4–8·0) to 10·4 years (5·7–15·2).1
Overall, 34 trials representing 11 969 patients were included in the meta-analysis. The 
control group of a four-arm trial4 was triplicated (ie, data for patients in the control group 
were copied twice to have three control arms to compare with each experimental arm), a 2 × 
2 trial (EORTC 2296245) included three relevant comparisons for the meta-analysis, and 
three three-arm trials36,37,55 included two relevant comparisons. The 33 trials included in the 
analysis of fractionation schedules (comparison 1) were divided into four predefined 
subgroups, depending on the type of radiotherapy: hyperfractionation (eight comparisons, 
including the unpublished EORTC 22962 trial),4,33,44,45,49,50,56 moderately accelerated 
radiotherapy (19 comparisons),2,4,30,32,34–39,41,42,46,54,55,57–59 very accelerated radiotherapy 
(seven comparisons, including the unpublished CHARTWEL trial),3,47,51–53,60 and 
moderately hypofractionated (dose per fraction between 2–2·5 Gy [two comparisons];31,40 
appendix pp 17–18). After discussion with the steering committee, the moderately 
hypofractionated trials were included in the moderately accelerated radiotherapy group. The 
analysis of altered fractionation radiotherapy versus conventional fractionation 
chemoradiotherapy (comparison 2) included five trials (four published36,37,43,55 and EORTC 
2296245). Patients’ characteristics by trial are presented in the appendix (pp 4–5).
33 trials and 11 423 patients (36 comparisons, 11 981 patients) were included in comparison 
1 (the analysis of fractionation schedules). Median follow-up was 7·9 years (IQR 5·3–12·1); 
it was less than 5 years for nine trials32,37,42,44,47,57,59 (including the two unpublished trials; 
1706 patients) and longer than 10 years for six trials2,4,46,50,54,56 (3519 patients). Patients 
were mostly male and had an Eastern Cooperative Oncology Group performance status of 0 
or 1 (appendix pp 6–7). Median age was 59 years (IQR 52–66). Tumours were mostly 
located in the oropharynx or larynx (9020 [75%] of 11 981 patients) and were stage III–IV 
for 8986 (75%) of 11 981 patients. Among 2922 stage I–II tumours, 2045 (70%) were 
laryngeal carcinomas. Patients’ characteristics are presented in the appendix (pp 6–7).
The results of all endpoints for comparison 1 are summarised in table 2. 8014 deaths 
occurred across all groups (appendix p 8). Altered fractionation radiotherapy was associated 
with a significant overall survival benefit compared with conventional radiotherapy (HR 
0·94, 95% CI 0·90–0·98; p=0·0033), with an absolute difference at 5 years of 3·1% (95% CI 
1·3–4·9) and at 10 years of 1·2% (–0·8 to 3·2; table 2, figures 1, 2A). Heterogeneity between 
trials was not significant (p=0·14, I2=20%). Interaction between the three altered 
fractionation regimens and the effect on overall survival was significant (p=0·051), the 
survival benefit being restricted to the hyperfractionated regimen (HR 0·83, 95% CI 0·74–
0·92), with absolute differences at 5 years of 8·1% (95% CI 3·4 to 12·8) and at 10 years of 
3·9% (–0·6 to 8·4; table 2, figures 1, 2B). The moderately accelerated and very accelerated 
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radiotherapy regimens did not have a significant effect on overall survival compared with 
conventional radiotherapy (table 2, figure 1, 2C, 2D).
For the secondary endpoint of progression-free survival, 8758 of 11 981 patients in 33 trials 
had a disease progression or died (table 2, appendix p 9). Compared with conventional 
radiotherapy, altered fractionation radiotherapy had a significant benefit on progression-free 
survival (table 2; figures 3, 4). Interaction between altered fractionation regimens and the 
effect on progression-free survival was not significant (p=0·17). Heterogeneity between 
trials was significant (p=0·045, I2=30%). The exclusion of the outlying CAIR trial58 
removed heterogeneity (p=0·55, I2=0%), without modifying the overall HR and the 
interaction between altered fractionation regimens (table 2).
In the 11 981 patients included in comparison 1, there were 5789 cancer-related deaths, 2225 
non-cancer-related deaths, 2189 local failure events, 1729 regional failure events, and 1326 
distant failure events (table 2; appendix p 9). Altered fractionation radiotherapy was 
associated with significantly reduced cancer mortality, local failure, and regional failure 
(table 2). No significant differences were reported between conventional radiotherapy and 
altered fractionation radiotherapy in terms of non-cancer mortality or distant failure (table 
2). Although no interaction was reported between altered fractionation regimens and the 
effect on local or regional control, hyperfractionation was associated with a reduction in 
local and regional failures (table 2). Moderately accelerated radiotherapy was only 
associated with a reduction in local failures (table 2), and very accelerated radiotherapy had 
no effect on any of these endpoints (table 2; appendix pp 19–27). Similar results were noted 
with competing risk methods for local, regional, and distant failures (data not shown).
Planned subset analyses showed no significant interaction between the effect on overall 
survival and the period of accrual (ie, included in the first round of MARCH vs in the 
present update [p=0·94]; postoperative vs definitive radiotherapy [p=0·45]; and trials 
including only larynx carcinomas vs the others [p=0·70]; appendix p 10). For the subset 
analysis regarding chemotherapy, five trials included the same concurrent chemotherapy in 
both treatment groups. The altered fractionation radiotherapy was hyperfractionation for one 
trial that was terminated early (EORTC 22962)45 and moderately accelerated radiotherapy 
for the four others.30,36,39,42 None used adjuvant chemotherapy and only one used 
induction.42 The effect of altered fractionation radiotherapy did not differ between trials 
with and without chemotherapy in both groups (p=0·39; appendix p 10). Similar results were 
found for progression-free survival (appendix p 10). After the exclusion of the nine 
comparisons with unusual radiotherapy regimens (hypofractionated radiotherapy,31,40 split 
course,4,30,55,57 or both hyperfractionated and moderately accelerated radiotherapy)44 or 
confounded chemotherapy schedules (ie, different chemotherapy regimens between 
groups),36,39 no significant interaction was found between type of fractionation and overall 
survival (p=0·11; appendix pp 28–29).
Planned subgroup analyses showed no significant interaction between treatment effect on 
progression-free survival and age (p=0·052). We found a reduction in treatment effect when 
age increased for progression-free survival (p=0·016) and when follow-up was censored at 
year 5 for those alive 5 years after randomisation for overall survival (p=0·026). We found 
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no interaction between treatment effect on overall survival or progression-free survival and 
patient performance status, sex, site of primary tumour, and tumour stage (appendix pp 11–
13). In the subset of hyperfractionation trials, we found no interaction with the five studied 
covariates (data not shown).
The effect of altered fractionation radiotherapy on regional control according to nodal status 
was studied as an unplanned post-hoc analysis. In the 5592 node-positive patients, we found 
a significant improvement in regional control with altered fractionation radiotherapy 
compared with conventional fractionation radiotherapy (HR 0·88, 95% CI 0·79–0·98; 
p=0·017; appendix p 30). This effect was not significantly different (p=0·060) according to 
the type of altered radiotherapy, but it was significant for hyperfractionated radiotherapy.
An unplanned analysis including all 33 trials and all patients (n=11981) was done to assess 
the evolution of the effect of altered fractionation radiotherapy over time (appendix pp 31–
32). The HR for death was 0·92 (95% CI 0·87–0·96) in the first 5 years after randomisation, 
and 1·04 (0·93–1·15) beyond 5 years, with a significant interaction between time and effect 
of altered fractionation radiotherapy (p=0·034; appendix p 31). Results were similar for 
progression-free survival, but the interaction between time and effect of altered fractionation 
radiotherapy was not significant (p=0·071; appendix p 32). The increase in restricted mean 
survival time in favour of altered fractionation radio therapy compared with conventional 
fractionation radiotherapy at 5-year versus 10-year horizons was 1·5 months (95% CI 0·5–
2·5) versus 3·3 months (1·3–5·4) for overall survival, and 2·7 months (1·5–3·9) versus 4·9 
months (2·7–7·1) for progression-free survival. When only hyperfractionated trials were 
analysed, these increases were 3·9 months (95% CI 1·9–5·9) versus 7·1 months (2·9–11·3) 
for overall survival, and 4·6 months (2·4–6·8) versus 8·2 months (3·8–12·5) for progression-
free survival.
The toxicity analysis showed a significantly increased prevalence of acute mucositis (OR 
2·02, 95% CI 1·81–2·26) and need for a feeding tube during treatment (1·75, 1·49–2·05) for 
patients treated with altered fractionation radiotherapy compared with those given 
conventional radiotherapy (table 3). Acute dermatitis was significantly increased in patients 
treated with altered fractionation radiotherapy only in the sensitivity analysis without trials 
responsible for the statistical heterogeneity (table 3). None of the late toxicities with 
sufficient available data showed an increased prevalence with the use of altered fractionation 
radiotherapy (table 3).
Five trials and 986 patients36,37,43,45,55 were included in comparison 2 (conventional 
fractionation radiotherapy plus concomitant chemotherapy vs altered fractionation 
radiotherapy alone; table 1). Median follow-up was 5·4 years (IQR 4·7–8·2), was less than 5 
years for two trials37,45 (n=161), and longer than 10 years for one trial43 (n=136). One 
trial,36 which compared chemoradiotherapy with very accelerated radiotherapy, accounted 
for 560 (57%) of 986 patients and 403 (59%) of 684 deaths in this comparison. Stage III 
tumours were found in 216 (22%) of 986 patients’ and stage IV tumours were found in 755 
(77%) of 986 patients. Most tumours were located in the oropharynx (appendix pp 14–15). 
Altered fractionation radiotherapy was associated with a significant decrease in overall 
survival compared with concomitant chemo radiotherapy (HR 1·22, 95% CI 1·05–1·42; 
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p=0·0098; figure 5), with absolute differences at 5 years of –5·8% (95% CI –11·9 to 0·3) and 
at 10 years of –5·1% (–13·0 to 2·8; appendix p 33). We found no significant heterogeneity 
between trials (figure 5). Progression-free survival was shorter with altered fractionation 
radiotherapy than with concomitant chemoradiotherapy (appendix pp 34–35). A decrease in 
locoregional control was seen with altered fractionation radiotherapy versus concomitant 
chemoradiotherapy but no difference was seen for distant control (appendix pp 36–39). No 
specific analysis was done for local or regional control because of the low number of 
patients in this comparison. Toxicities were not analysed for this comparison because of 
insufficient data.
Discussion
This updated individual patient data meta-analysis confirmed, with nearly twice as many 
patients and a longer follow-up than in the first round of the MARCH meta-analysis,1 that 
altered fractionation radiotherapy was associated with a small but significant improvement 
in overall survival when compared with standard fractionation radiotherapy. However, this 
improvement in overall survival was slight in the overall population (3·1% at 5 years) and 
was only significant in the hyperfractionated radiotherapy group. There was a significant 
interaction between the effect on overall survival and altered fractionation regimens, and the 
absolute difference at 5 years was 8·1% for the hyperfractionation group. The survival 
benefit decreased when age increased when follow-up was censored at 5 years, but was 
otherwise consistent in all patient subgroups. There was a clear benefit on local control, a 
smaller benefit on regional (nodal) control and cancer mortality, and no benefit on distant 
metastases and non-cancer-related mortality. Altered fractionation radiotherapy was 
associated with increased acute mucositis and need for feeding tube placement but we found 
no significant difference in late toxicity between conventional and altered fractionated 
radiotherapy. The new meta-analysis of trials investigating the direct comparison between 
altered fractionation radiotherapy and concomitant chemo radiotherapy showed the 
superiority of concomitant chemoradiotherapy regarding overall survival, progression-free 
survival, and locoregional control.
The strengths of this meta-analysis are its size and the use of individual patient data, which 
allowed detailed checking of each trial that was subsequently reanalysed and validated by 
the trialists. Unpublished trials were also included to avoid publication bias because positive 
trials are known to be published more frequently than negative trials, especially in the 
English language medical literature.61,62 We found no significant overlap between our 
definitions of fractionation, meaning that a trial could be included in only one type of 
fractionation group. The steering committee was consulted if a discussion about the 
fractionation category was necessary. The intention-to-treat principle was respected for all 
analyses. The reproducibility of the findings regarding overall survival and progression-free 
survival between the first round of the meta-analysis1 and the new trials included in this 
update—as shown by the absence of interaction between meta-analysis round and treatment 
effect—is an indicator of the robustness of the findings. At the time of this update, seven 
trials representing 3655 patients had a follow-up of longer than 10 years,2,4,43,46,50,54,56 
which enabled long-term analyses to be done. The large number of patients allowed 
secondary endpoints to be assessed and subgroup and subset analyses to be done with 
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adequate power. Finally, the collection of toxicity data allowed the analysis of the pattern of 
adverse events associated with altered fractionation radiotherapy.
This second round of the meta-analysis provided a hypothetical explanation for the 
superiority of hyperfractionation over the other altered fractionation regimens. 
Hyperfractionation was associated with a benefit both in local and regional control whereas 
accelerated regimens only provided an improvement in local control. When the analysis was 
restricted to node-positive patients, the interaction between altered fractionated regimens and 
regional control was not significant, but the effect of altered fractionated radiotherapy was 
significant only for hyperfractionated radiotherapy. The explanation for this difference on 
nodal control favouring hyperfractionation is unclear, but might be related to the increase in 
absolute dose provided by hyperfractionation. Pure acceleration (the delivery of 66–70 Gy in 
5·5–6 weeks) should therefore be considered only for patients with a low nodal burden.
This meta-analysis has several limitations. First, almost all of the trials included used 
outdated radiotherapy techniques (two-dimensional or three-dimensional radiotherapy), 
which is a concern because intensity-modulated radiotherapy is the present standard of care 
for head and neck cancers. However, the dose-intensity– efficacy association shown in this 
meta-analysis certainly remains valid, even in the intensity-modulated radiotherapy era 
because dose to gross tumour has not changed and is around 2 Gy per fraction. Hyper 
fractionation or acceleration can be done with intensity-modulated radiotherapy in the same 
way as they were done with two-dimensional radiotherapy and no reason exists to expect a 
different efficacy profile. The included trials also come before the human papillomavirus 
(HPV) era and often did not record smoking status, with data for these variables available in 
very few trials in the meta-analysis. Because positivity for HPV is a major prognostic factor 
in oropharyngeal carcinoma,39 extensive analyses will be done in trials that provided data 
about HPV and smoking status in the search for prognostic and predictive markers of 
fractionation modification efficacy.
The trials’ accrual period ranged from 1979 to 2010 and this long time span might add 
heterogeneity to the meta-analysis, although no interaction between meta-analysis round and 
overall survival or progression-free survival was recorded. A further limitation concerns the 
quality of data collected for the toxicity analysis. Although this analysis was planned, it was 
based on a limited subset of trials for which these data were available, and was not feasible 
for comparison 2 because of insufficient data. Third, only five trials compared altered 
fractionation radiotherapy with standard radiotherapy plus chemotherapy in both groups, and 
three trials have a lower dose of chemotherapy in the group with altered fractionation 
radiotherapy than in the standard radiotherapy group.30,36,39 Last, the important number of 
endpoints analysed raises the question of multiplicity of testing and the inflation of type I 
error. Overall survival was the primary endpoint of the meta-analysis. Regarding secondary 
endpoints, most analyses presented in this Article were prespecified. Subset (by trial 
characteristics) or subgroup (by patient characteristics) analyses are regarded as a lower 
level of evidence than the analyses on overall population. They are mostly explanatory or 
hypothesis generating. The readers should pay careful attention to the consistency between 
the results obtained across the different endpoints, which reinforces the confidence in the 
analysis.
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The direct comparison between altered fractionation radiotherapy and concomitant 
chemoradiotherapy showed the superiority of the addition of concomitant chemotherapy 
over pure fractionation modification. This comparison provides an additional contribution to 
the bulk of randomised data, having shown the superiority of chemoradiotherapy over 
radiotherapy alone.5 This finding is also in agreement with the preliminary results of an 
ongoing network meta-analysis63 in which altered fractionation radiotherapy ranked lower 
than platinum-based concomitant chemoradiotherapy for overall and progression-free 
survival. Concomitant chemo radiotherapy should remain the standard of care for locally 
advanced node-positive tumours. Notably, however, the altered fractionation regimens used 
in this direct comparison were hyperfractionation for one trial,45 moderately accelerated 
radiotherapy for three trials,37,43,55 and very accelerated radiotherapy for one trial (which 
accounts for most of the data).36 Because hyperfractionation seemed superior to the other 
altered fractionation regimens in comparison 1, the comparison between concomitant 
chemoradiotherapy and hyperfractionation is relevant. This comparison cannot be made in 
this meta-analysis because of the low number of patients available for comparison 2. The 
comparison between concomitant chemoradiotherapy and hyperfractionation remains to be 
done and there is currently no suggestion that one treatment would perform better than the 
other because the difference in overall survival at 5 years in favour of hyperfractionation in 
this meta-analysis was 8·1% and very close to the overall survival results reported in the last 
update of the MACH-NC meta-analysis5 for concomitant chemotherapy plus radiotherapy 
(6·5%). The ongoing network meta-analysis will try to answer that question.
Ongoing research efforts using the MARCH database also include extensive analysis of 
trials that provided information about the pathology findings for patients who have 
undergone primary surgery followed by postoperative radiotherapy. The findings might 
provide new insights into the radiotherapy dose fractionation issue in the postoperative 
setting, which remains a controversial area. Other areas of improvement should include cost-
effectiveness analyses comparing concomitant chemoradiotherapy and hyperfractionation 
radiotherapy without concomitant chemotherapy, health services research to address 
patients’ and physicians’ difficulties in the implementation of hyperfractionation 
radiotherapy, and improved documentation of long-term toxicity and patient reported 
outcomes.
In conclusion, this updated individual patient data meta-analysis confirms the efficacy of 
altered fractionation radiotherapy over conventional fractionation radiotherapy and the 
superiority of hyperfractionated radiotherapy over the other altered fractionation 
radiotherapy schedules. The effect of a moderate acceleration is limited to local control, 
whereas hyperfractionation seems to improve both local and regional control, and might 
therefore be preferred for patients with node-positive tumours. The direct comparison 
between altered fractionation radiotherapy and concomitant chemoradiotherapy suggests the 
superiority of concomitant chemoradiotherapy. Further research is still needed to compare 
efficacy of hyperfractionated radiotherapy and con comitant chemoradiotherapy, and to look 
for predictive markers of treatment efficacy.
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Research in context
Evidence before this study
The Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) based 
on 15 trials and 6515 patients showed that altered fractionation radiotherapy is associated 
with improved overall survival and progression-free survival when compared with 
conventional fractionation radiotherapy. For this update, we searched PubMed, Web of 
Science, Cochrane Controlled Trials meta-register, ClinicalTrials.gov, and meeting 
proceedings, without language restriction, for published and unpublished “randomized 
trials” of “radiotherapy fractionation” in “head and neck cancer” published or presented 
between Jan 1, 2009, and July 15, 2015. Randomised trials comparing conventional 
fractionation radiotherapy with altered fractionation radiotherapy (with or without the 
same concomitant chemotherapy in both groups), or conventional fractionation 
radiotherapy plus concomitant chemotherapy versus altered fractionation radiotherapy 
alone, in patients with non-metastatic squamous cell carcinoma were eligible as long as 
they had started randomisation on or after Jan 1, 1970, and completed accrual before Dec 
31, 2010. For the trials previously included in the first round of MARCH, a follow-up 
update was requested.
Added value of this study
Individual patient data meta-analyses of randomised trials provide the highest level of 
evidence. This update of the MARCH meta-analysis almost doubled the number of 
patients and trials included, reaching 34 trials and 11 969 patients. The median follow-up 
was increased, and is now 7·9 years overall (IQR 5·3–12·1) and 10·4 years (5·7–15·2) for 
the 15 trials previously included in the MARCH meta-analysis. Data on acute and late 
toxicity were collected. Finally, a separate meta-analysis was done that compared altered 
fractionation radiotherapy and concomitant chemoradiotherapy. Altered fractionation 
radiotherapy was associated with a significant overall survival benefit compared with 
conventional fractionation. However, the overall survival benefit was restricted to the 
hyperfractionated group due to a significant interaction between type of fractionation and 
treatment effect. Progression-free survival was improved by altered fractionation 
radiotherapy, without a significant difference between type of fractionation, through an 
improvement in local and regional control. Acute mucositis and the need for a feeding 
tube during treatment were increased in the altered fractionation group but late toxicities 
were similar between the groups. Altered fractionation radiotherapy had significantly 
lower overall survival compared with conventional radiotherapy plus concomitant 
chemotherapy although the altered fractionation regimens of trials in this comparison 
were mainly accelerated radiotherapy, which has not been shown to increase survival 
compared with conventional fractionation.
Implications of all the available evidence
This updated meta-analysis confirms the efficacy of altered fractionation radiotherapy 
over conventional fractionation radiotherapy and the superiority of hyperfractionated 
radiotherapy over the other altered fractionation radiotherapy schedules. The effect of 
accelerated radiotherapy is limited to local control, whereas hyperfractionated 
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radiotherapy seems to improve both local and regional control, and might therefore be 
preferred for patients with node-positive tumours. Hyperfractionated radiotherapy should 
therefore be regarded as a standard of care along with concomitant chemoradiotherapy 
for the treatment of locally advanced head and neck cancers. Head-to-head comparisons 
between hyperfractionated radiotherapy and concomitant chemoradiotherapy are scarce
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Figure 1. Overall survival for trials comparing altered fractionation and conventional 
fractionation radiotherapy
The area of each plotted square is proportional to the number of deaths in each trial. The 
vertical dashed line represents the overall pooled HR. The exclusion of the outlying CAIR 
trial58 reduced the heterogeneity further (p=0·89, I2=0%), increasing the statistical 
interaction between altered fractionation regimens and survival (p=0·033) without affecting 
the overall effect of altered fractionation radiotherapy on survival. HR=hazard ratio.
Lacas et al. Page 19
Lancet Oncol. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Overall survival curves for trials comparing altered fractionation and conventional 
fractionation radiotherapy
(A) All types of altered fractionation radiotherapy. (B) Hyperfractionated radiotherapy. (C) 
Moderately accelerated radiotherapy. (D) Very accelerated radiotherapy.
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Figure 3. Progression-free survival for trials comparing altered fractionation and conventional 
fractionation radiotherapy
The area of each plotted square is proportional to the number of progression events or deaths 
in each trial. The vertical dashed line represents the overall pooled HR. HR=hazard ratio.
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Figure 4. Progression-free survival curves for trials comparing altered fractionation and 
conventional fractionation radiotherapy
(A) All types of altered fractionation radiotherapy. (B) Hyperfractionated radiotherapy. (C) 
Moderately accelerated radiotherapy. (D) Very accelerated radiotherapy.
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Figure 5. Overall survival for trials comparing altered fractionation radiotherapy and 
concomitant chemoradiotherapy (using conventional fractionation)
The area of each plotted square is proportional to the number of deaths in each trial. The 
vertical dashed line represents the overall pooled HR. HR=hazard ratio.
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